S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

ASLAN Pharmaceuticals Stock Forecast, Price & News

+0.01 (+0.93%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
175,957 shs
Average Volume
186,530 shs
Market Capitalization
$41.03 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ASLN News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASLAN Pharmaceuticals logo

About ASLAN Pharmaceuticals

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and AhR Antagonist. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$3 million
Book Value
($0.32) per share


Net Income
$-16.20 million
Pretax Margin




Free Float
Market Cap
$41.03 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.85 out of 5 stars

Medical Sector

766th out of 1,405 stocks

Pharmaceutical Preparations Industry

370th out of 678 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

ASLAN Pharmaceuticals (NASDAQ:ASLN) Frequently Asked Questions

Is ASLAN Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASLAN Pharmaceuticals stock.
View analyst ratings for ASLAN Pharmaceuticals
or view top-rated stocks.

How has ASLAN Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

ASLAN Pharmaceuticals' stock was trading at $1.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ASLN shares have decreased by 32.1% and is now trading at $1.08.
View which stocks have been most impacted by COVID-19

Are investors shorting ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals saw a decrease in short interest in December. As of December 31st, there was short interest totaling 94,400 shares, a decrease of 46.1% from the December 15th total of 175,100 shares. Based on an average daily trading volume, of 433,900 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the shares of the company are sold short.
View ASLAN Pharmaceuticals' Short Interest

When is ASLAN Pharmaceuticals' next earnings date?

ASLAN Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, April 28th 2022.
View our earnings forecast for ASLAN Pharmaceuticals

How were ASLAN Pharmaceuticals' earnings last quarter?

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) posted its quarterly earnings results on Monday, October, 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01.
View ASLAN Pharmaceuticals' earnings history

What price target have analysts set for ASLN?

3 analysts have issued 1 year target prices for ASLAN Pharmaceuticals' shares. Their forecasts range from $8.00 to $8.00. On average, they expect ASLAN Pharmaceuticals' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 640.7% from the stock's current price.
View analysts' price targets for ASLAN Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are ASLAN Pharmaceuticals' key executives?

ASLAN Pharmaceuticals' management team includes the following people:
  • Carl Aslan Jason Morton Firth, Chief Executive Officer & Director
  • Kiran Kumar Asarpota, Chief Operating Officer & Head-Finance
  • Kenneth Kobayashi, Chief Medical Officer
  • Stephen Doyle, Chief Business Officer
  • Ferda Cevikbas, Executive Director & Head-Translational Science

What other stocks do shareholders of ASLAN Pharmaceuticals own?

When did ASLAN Pharmaceuticals IPO?

(ASLN) raised $60 million in an initial public offering on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

What is ASLAN Pharmaceuticals' stock symbol?

ASLAN Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASLN."

How do I buy shares of ASLAN Pharmaceuticals?

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ASLAN Pharmaceuticals' stock price today?

One share of ASLN stock can currently be purchased for approximately $1.08.

How much money does ASLAN Pharmaceuticals make?

ASLAN Pharmaceuticals has a market capitalization of $41.03 million and generates $3 million in revenue each year. The company earns $-16.20 million in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does ASLAN Pharmaceuticals have?

ASLAN Pharmaceuticals employs 2,020 workers across the globe.

What is ASLAN Pharmaceuticals' official website?

The official website for ASLAN Pharmaceuticals is www.aslanpharma.com.

Where are ASLAN Pharmaceuticals' headquarters?

ASLAN Pharmaceuticals is headquartered at 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920.

How can I contact ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals' mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at (656) 222-4235, via email at [email protected], or via fax at 65-6225-2419.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.